ISRCTN47701105已完成不适用
TRI-stent Adjudication Study - Low risk of Restenosis
Academic Medical Centre (AMC) (Netherlands)0 个研究点目标入组 1,260 人开始时间: 2007年8月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Clinically stable patients undergoing a Percutaneous Coronary Intervention (PCI) for a coronary artery lesion with a low risk of restenosis are candidates for entry into this study.
- •A target lesion is considered to be at a low risk of restenosis if all of the following apply:
- •1. A de novo lesion located in a native epicardial vessel with a Reference Vessel Diameter (RVD) greater than 2.8 mm by visual estimation
- •2. A de novo lesion with a length of smaller than 20 mm by visual estimation
- •3. A de novo lesion with a Thrombolysis in Myocardial Infarction (TIMI) flow equal to or greater than 1
- •4. The patient does not have diabetes mellitus
排除标准
- •1. Younger than 18 years of age
- •2. A target lesion located in the left main coronary artery
- •3. A Chronic Totally Occluded (CTO) target lesion
- •4. A target lesion with involvement of a side branch, which is equal to or greater than 2.0 mm in diameter by visual estimation
- •5. A restenotic target lesion
- •6. A target lesion in an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft
- •7. A target lesion(s) with an indication for treatment with a Drug-Eluting Stent (DES)
- •8. Urgent need for revascularisation
- •9. ST Elevation Myocardial Infarction (STEMI) within the past six weeks
- •10. Ventricular tachyarrhythmias within the past week
- •11. A diabetic patient
- •12. Known renal insufficiency (e.g. serum creatinine level of more than 200 µgram/L)
- •13. Platelet count of less than 100,000 cells/mm^3 or more than 700,000 cells/mm^3, a White Blood Cell (WBC) count of less than 3,000 cells/mm^3, or documented or suspected liver disease (including laboratory evidence of hepatitis)
- •14. History of a bleeding diathesis, or evidence of active abnormal bleeding within 30 days of randomisation
- •15. History of a hemorrhagic stroke at any time, or stroke or Transient Ischaemic Accident (TIA) of any aetiology within 30 days of randomisation
- •16. Previous or scheduled chemotherapy or radiotherapy within 30 days prior or after the procedure
- •17. On immune-suppression therapy or with known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)
- •18. Severe hypertension (systolic blood pressure greater than 180 mmHg or diastolic blood pressure over 100 mmHg, after treatment)
- •19. Contraindication for treatment with the Genous™ EPC capturing stent, such as previous administration of murine therapeutic antibodies and exhibition of sensitisation through the production of Human Anti-Murine Antibodies (HAMA)
- •20. Known hypersensitivity or contraindication to aspirin, heparin or clopidogrel
- •21. Elective surgery, planned within the first six months after the procedure that requires discontinuing either aspirin or clopidogrel
- •22. Previous heart transplant or any other organ transplant
- •23. Previous participation in this study
- •24. Circumstances that prevent follow-up (no permanent home or address, transient, etc.)
- •25. Women who are pregnant or who are of childbearing potential who do not use adequate contraception
研究者
相似试验
已完成
不适用
TRI-stent Adjudication Study - High risk of RestenosisCoronary artery lesions with a high risk of restenosis and an indication for percutaneous coronary treatmentCirculatory SystemOther disorders of arteries and arteriolesISRCTN74297220Academic Medical Centre (AMC) (Netherlands)1,300
招募中
1 期
TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis.CTIS2022-501027-25-01CHU De Rennes430
招募中
不适用
Efficacy and patient satisfaction in bowel cleansing protocols using polyethylene glycol-ascorbic acid (PEG) and picolyteKCT0004218Korea University Anam Hospital330
进行中（未招募）
1 期
A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids - Study of Zoster vaccine in subjects on chronic steroid maintenanceZoster VaccineMedDRA version: 8.1 Level: LLT Classification code 10019974 Term: Herpes zosterEUCTR2006-003651-20-GBMerck & Co Inc.,300
进行中（未招募）
不适用
A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids - Study of Zoster vaccine in subjects on chronic steroid maintenanceZoster VaccineMedDRA version: 8.1Level: LLTClassification code 10019974Term: Herpes zosterEUCTR2006-003651-20-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300